SCHEMBL16423136

SCHEMBL16423136

O=C(O)N1CC[C@](O)(c2ccc(F)c(Cl)c2)[C@@H](O)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 4/20 0.41
CCR1 P32246 1/20 0.39
IDO1 P14902 1/20 0.37
MAPT P10636 2/20 0.37
PSEN1 P49768 2/20 0.36
PSEN2 P49810 2/20 0.36
APH1B Q8WW43 2/20 0.36
NCSTN Q92542 2/20 0.36
APH1A Q96BI3 2/20 0.36
PSENEN Q9NZ42 2/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A4 P31645 1/20 0.36
HTR1A P08908 1/20 0.36
OPRK1 P41145 2/20 0.36
OPRM1 P35372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6042399 0.84 KMT2A (0.49) MAPTALDH1A1LMNAKMT2ADRD2
SCHEMBL16434862 0.83 ALK (0.46) SLC6A3CCR1MAPTKMT2A
SCHEMBL16423307 0.83 RORC (0.42) SLC6A3KMT2AOPRK1OPRM1OPRD1
SCHEMBL4614574 0.82 SLC6A3 (0.49) SLC6A3CCR1KMT2ADRD2DRD4
SCHEMBL4666335 0.82 SLC6A3 (0.49) SLC6A3CCR1KMT2ADRD2DRD4
SCHEMBL16422536 0.82 SLC6A3 (0.49) SLC6A3CCR1KMT2ADRD2DRD4
SCHEMBL16422376 0.80 SLC6A3 (0.37) SLC6A3CCR1MAPTALDH1A1LMNA
SCHEMBL5380104 0.79 CCR1 (0.50) CCR1MAPTKMT2ADRD2DRD4
SCHEMBL2246366 0.77 OPRK1 (0.49) MAPTALDH1A1LMNAKMT2AOPRK1
SCHEMBL2242094 0.77 OPRK1 (0.49) MAPTALDH1A1LMNAKMT2AOPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2832728-B1 TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR NISSAN CHEMICAL IND LTD (JP) 2018-09-05 EP disclosed
US-9403798-B2 Triazinone compound and T-type calcium channel inhibitor NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-08-02 US disclosed
US-20150065705-A1 TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR NISSAN CHEMICAL CORPORATION (JP) 2015-03-05 US disclosed
EP-2832728-A1 TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR Nissan Chemical Industries, Ltd. (JP) 2015-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150065705-A1 TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR CACNA1E, CACNA1I, CACNA1G SLC6A3 783/4885CCR1 2888/4885IDO1 4300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.